Immune Oncology Research Institute

📬Article of the Week📜 Suggested by the #BPDCN International Registry❗️-Astghik Voskanyan 📋 Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting 🖍 The Armenian #BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) Register likely refers to a specialized database or registry in Armenia focused on collecting, analyzing, and managing data related to BPDCN, a rare and aggressive form of blood cancer. This kind of registry would be crucial for gathering epidemiological data, understanding disease prevalence in the Armenian population, monitoring treatment outcomes, and potentially guiding research and clinical practice in managing BPDCN.  We are pleased to announce that the BPDCN team's original abstract has been published on the Cancer Network site, a specialized online platform that provides information, resources, and support related to cancer. The abstract presents a case of a patient diagnosed with #BPDCN, highlighting key challenges, treatment approaches, and diagnostic criteria associated with the disease. 🖍Authors:Nerses Ghahramanyan ,Elen Baloyan ,Gevorg Tamamyan , Fiza Khan ,Md Foorquan Hashmi ,Naveen Pemmaraju, MD ,Astghik Voskanyan , et al. ⬇️https://lnkd.in/dAvZ6bsG #BPDCN, #oncology, #Tagraxofusp, #Armenianregistry, #cancer.

📬Article of the Week📜 Suggested by the #BPDCN International Registry❗️-Astghik Voskanyan 🔖 Real world (RW) study of patients (pts) with relapsed or refractory (RR) blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG). 🔖 #TAG showed rapid, durable responses and a high response rate in RR BPDCN patients, leading to extended survival in a population with poor prognosis, where previous treatments have been less effective. These real-world findings support TAG as a treatment option for RR #BPDCN patients. 🔖Authors:David Manteigas ,Mike Zuurman ,Eric DECONINCK , etc.⬇️ https://lnkd.in/dwsBPE5N #Tagraxofusp, #BPDCN, #article, #treatment,#cancer

📬Article of the Week📜 Suggested by the #BPDCN International Registry❗️-Astghik Voskanyan 📮 North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need ❗️ The North American BPDCN Consortium (#NABC) is a collaborative group of multidisciplinary experts focused on advancing BPDCN care. Their main goals include increasing awareness, defining MRD testing, and exploring non-HSCT treatment approaches. They aim to develop combination therapies, understand BPDCN’s pathobiology, address pediatric cases, and improve quality of life measurements. Additionally, the consortium seeks to create risk stratification tools, expand clinical trial access, and secure funding to support future research and treatment innovations in BPDCN. 📜Authors:Naveen Pemmaraju, MD ,Kendra Sweet ,Jayastu Senapati ,Arthur Frankel , Maria Teresa Garcia Romero , Norma Ruth López Santiago , et al.⬇️ https://lnkd.in/dR_77NT8 #BPDCN, #internationalregistry, #NABC, #oncology, #hematology, #Tagraxofusp

🔖 ASSESSMENT OF THE SAFETY AND EFFICACY OF BALSTILIMAB IN COMBINATION WITH BOTENSILIMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER (IMMONC0008) - NCT06322108 📰 #IMMONC, in collaboration with #Agenus, has launched a new trial, which will assess the safety and efficacy of the anti-CTLA-4 agent (#botensilimab in combination with anti-PD-1 antibody #balstilimab in the frontline treatment of metastatic non-small cell lung cancer (NSCLC). 🔖 The study will enroll participants with a histologically confirmed diagnosis of metastatic #NSCLC and without targetable EGFR mutation or ALK rearrangement, while excluding those with untreated brain #metastases or oligometastatic disease lacking targetable lesions. The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods. 📜The Principal Investigator of the trial is Dr. Samvel Bardakhchyan, the study team includes Prof. Gevorg Tamamyan Dr. Davit Zohrabyan , Dr. Liana Safaryan, and Dr. Amalya Sargsyan. Agenus #oncology, #balstilimab, #metastases,#NSCLC, #ClinicalTrial,#ImmuneOncology,#Chemotherapy, #Immunotherapy, #Agenus,#Botensilimab,#LungCancer.⬇️

📬Article of the Week📜 Suggested by the #BPDCN International Registry❗️-Astghik Voskanyan 🔖Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of #tagraxofusp and clinical considerations❗️ 🔖Authors:Naveen Pemmaraju, MD ,David Rizzieri , Raajit Rampal ,Eunice S. Wang MD ,James Foran ,et al.⬇️ 📜 https://lnkd.in/dZfbN--3 #BPDCN, #Immuneoncology, #article,#Tagraxofusp,#neoplasm

❗️❗️❗️ GREAT NEWS❗️❗️❗️ 📈We are excited to share that this October, Dr. Karl Balabanian, #Research Director at INSERM and leader of the “#Chemokines, Lymphoid Niches, and #Immunopathology” team at Saint-Louis Hospital and the INSERM U1160 unit, will be visiting Armenia. During his visit, he will engage with the teams at the #ImmuneOncology Research Institute and the Yeolyan #Hematology and #Oncology Center. During the meeting, he will give a presentation on his abstract titled 🖍 '#CXCR4 signaling, a gatekeeper orchestrating the bone marrow ecosystem'. ⬇️ https://lnkd.in/dkhK_8z3 #Immuneoncology, #Hematology, #Oncology, #Immunopathology, #molecular, #aricle, #author

🎉We are pleased to announce, that Shushan Hovsepyan is appointed as Innovation and Development Director at the Immune Oncology Research Institute❗️-Shushan Hovsepyan 🖍 https://lnkd.in/edSWidKE #immuneoncology, #oncodaily, #oncology, #innovation ,#researchinstitute

📰Article of the day❗️Suggested by the Immune Oncology Research Institute 📍 Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial 🖍️Authors:Andrea Bullock ,Marwan Fakih ,Apostolia M Tsimberidou,Joseph Grossman,Breelyn Wilky, MD ,Daruka Mahadevan MD PhD, ANI BALMANOUKIAN ,Gary Schwartz, MD ,Ghassan Abou-Alfa, Neil Segal ,Bruno Bockorny MD FACP ,Jaymin Patel, Katherine Rosenthal RN, MSN, OCN, CCRP , et al. ⬇️ https://lnkd.in/gZwrpU76 #cancer, #aricleoftheday

📰Article of the day❗️Suggested by the Immune Oncology Research Institute 📈 Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma ❗️Authors: Ingo Mellinghoff , Martin J van den Bent , Deborah Blumenthal , Mehdi Touat , Jennifer Clarke , Shlomit Yust-Katz , francois ducray , Yoshie Umemura , Louis Nabors , Holdhoff Matthias , Andreas Hottinger , Yoshiki Arakawa , Wolfgang Prof Wick , Riccardo Soffietti , Pierre Giglio , Macarena De la Fuente , Timothy Cloughesy ,et al. 🔖Author Affiliations: Memorial Sloan Kettering Cancer Center, Erasmus MC , Tel Aviv Medical Center , RABIN MEDICAL CENTER , Sorbonne Université , Institut du Cerveau – Paris Brain Institute , Hospices Civils de Lyon - HCL , CRCL Centre de Recherche en Cancérologie de Lyon , Duke University , Huntsman Cancer Institute , The Royal Marsden NHS Foundation Trust , Princess Margaret Cancer Centre , Sunnybrook , MIRO Cancer Centers/ Michigan Comprehensive Cancer Institute , Hospital Universitario 12 De Octubre , The Ohio State University Wexner Medical Center ,et al. ⬇️ https://lnkd.in/eVVum4XK

📰Article of the day❗️Suggested by the Immune Oncology Research Institute 📈 Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer ❗️Authors:Nanda Horeweg, Remi Nout ,Stephanie de Boer ,Karen Verhoeven-Adema ,Hein Putter ,Tjalling Bosse,et al. 📋Author Affiliations: Leiden University ,UMC Utrecht ,Maastricht University ,Medisch Spectrum Twente ,Erasmus MC ,et al. ⬇️ https://lnkd.in/d6P2RyaT #cancer,#oncology,#article, #immuneoncology